Please assess the completion status of the following clinical trial:

Trial Title: Japan Alteplase Clinical Trial (J-ACT): Efficacy and Safety Study of Tissue Plasminogen Activator (Alteplase) for Ischemic Stroke

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Patients with acute ischemic stroke within 3 hours of onset, with a clearly defined time of onset~Exclusion Criteria:~1. patients with rapidly improving neurological symptoms or with minor neurological deficit (National Institutes of Health Stroke Scale (NIHSS) score of ≤4) prior to the start of treatment~2. Computed Tomography (CT) evidence of non-minor early ischemic signs (minor early ischemic sign was defined as the involvement of one-third or less of the middle cerebral artery area)~3. CT evidence of cerebral hemorrhage or subarachnoid hemorrhage~4. symptoms suggestive of subarachnoid hemorrhage~5. lactation, pregnancy or suggestive pregnancy; menstruation~6. platelet count below 100,000/mm3~7. heparin administration within 48 hours preceding stroke onset with an elevated activated partial thromboplastin time (APTT); current use of oral anticoagulants with an International Normalized Ratio (INR) of ≥1.7; use of drugs not allowed to be administered concomitantly with alteplase (other thrombolytic agents, ozagrel sodium, argatroban and edaravone) prior to the study treatment~8. major surgery or serious trauma within the preceding 14 days; serious head or spinal cord trauma within the preceding 3 months~9. a history of gastrointestinal or urinary tract hemorrhage within the previous 21 days~10. arterial puncture at a noncompressible site within the preceding 7 days~11. a history of stroke within the preceding 3 months; a history of intracranial hemorrhage or increased risk of intracranial hemorrhage because of cerebral aneurysm, arteriovenous malformation, neoplasm, etc.~12. concurrent severe hepatic or renal dysfunction~13. malignant tumor under treatment~14. a systolic blood pressure of \>185 mmHg or diastolic blood pressure of \>110 mmHg~15. a need for aggressive treatment to reduce blood pressure to below these limits(14))~16. blood glucose levels of \<50 mg/dL or \>400 mg/dL~17. acute myocardial infarction(AMI) or endocarditis after AMI~18. concurrent infectious endocarditis, moya-moya disease (Willis circle occlusion syndrome), aortic dissection, neck trauma, etc.; strong suspicion of ischemic cerebrovascular disorder caused by non-thrombotic occlusion or any other hemodynamic condition~19. seizure at the onset of stroke~20. coma (a Japan Coma Scale score of ≥100)~21. an mRS score of ≥2 before stroke onset~22. a history of hypersensitivity to protein preparations~23. difficulty in monitoring for 3 months~24. less than 3 months since any other clinical trial

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Alteplase (Type: EXPERIMENTAL): 0.6mg/kg intravenous alteplase with 10% being administered as a bolus followed by continuous infusion of the remainder over 1 hour

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete